245 related articles for article (PubMed ID: 18725839)
21. Role of double-contrast barium enema in colorectal cancer screening based on fecal occult blood.
Ciatto S; Castiglione G
Tumori; 2002; 88(2):95-8. PubMed ID: 12088265
[TBL] [Abstract][Full Text] [Related]
22. Primary care, economic barriers to health care, and use of colorectal cancer screening tests among Medicare enrollees over time.
Doubeni CA; Laiyemo AO; Young AC; Klabunde CN; Reed G; Field TS; Fletcher RH
Ann Fam Med; 2010; 8(4):299-307. PubMed ID: 20644184
[TBL] [Abstract][Full Text] [Related]
23. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors.
Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ
Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138
[TBL] [Abstract][Full Text] [Related]
24. Validation of self-reported history of colorectal cancer screening.
Khoja S; McGregor SE; Hilsden RJ
Can Fam Physician; 2007 Jul; 53(7):1192-7. PubMed ID: 17872816
[TBL] [Abstract][Full Text] [Related]
25. Colorectal cancer screening with double-contrast barium enema: a national survey of diagnostic radiologists.
Klabunde CN; Jones E; Brown ML; Davis WW
AJR Am J Roentgenol; 2002 Dec; 179(6):1419-27. PubMed ID: 12438029
[TBL] [Abstract][Full Text] [Related]
26. Levels and variation in overuse of fecal occult blood testing in the Veterans Health Administration.
Partin MR; Powell AA; Bangerter A; Halek K; Burgess JF; Fisher DA; Nelson DB
J Gen Intern Med; 2012 Dec; 27(12):1618-25. PubMed ID: 22810358
[TBL] [Abstract][Full Text] [Related]
27. Using a multifaceted approach to improve the follow-up of positive fecal occult blood test results.
Singh H; Kadiyala H; Bhagwath G; Shethia A; El-Serag H; Walder A; Velez ME; Petersen LA
Am J Gastroenterol; 2009 Apr; 104(4):942-52. PubMed ID: 19293786
[TBL] [Abstract][Full Text] [Related]
28. Physicians' use of nonphysician healthcare providers for colorectal cancer screening.
Sansbury LB; Klabunde CN; Mysliwiec P; Brown ML
Am J Prev Med; 2003 Oct; 25(3):179-86. PubMed ID: 14507523
[TBL] [Abstract][Full Text] [Related]
29. Trends in colorectal cancer test use among vulnerable populations in the United States.
Klabunde CN; Cronin KA; Breen N; Waldron WR; Ambs AH; Nadel MR
Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1611-21. PubMed ID: 21653643
[TBL] [Abstract][Full Text] [Related]
30. Repeated Automated Mobile Text Messaging Reminders for Follow-Up of Positive Fecal Occult Blood Tests: Randomized Controlled Trial.
Azulay R; Valinsky L; Hershkowitz F; Magnezi R
JMIR Mhealth Uhealth; 2019 Feb; 7(2):e11114. PubMed ID: 30720439
[TBL] [Abstract][Full Text] [Related]
31. Reliability and validity of a questionnaire to measure colorectal cancer screening behaviors: does mode of survey administration matter?
Vernon SW; Tiro JA; Vojvodic RW; Coan S; Diamond PM; Greisinger A; Fernandez ME
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):758-67. PubMed ID: 18381467
[TBL] [Abstract][Full Text] [Related]
32. Validity of four self-reported colorectal cancer screening modalities in a general population: differences over time and by intervention assignment.
Jones RM; Mongin SJ; Lazovich D; Church TR; Yeazel MW
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):777-84. PubMed ID: 18381476
[TBL] [Abstract][Full Text] [Related]
33. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
34. Patient preferences for colorectal cancer screening.
Leard LE; Savides TJ; Ganiats TG
J Fam Pract; 1997 Sep; 45(3):211-8. PubMed ID: 9300000
[TBL] [Abstract][Full Text] [Related]
35. Population screening for colorectal cancer: advantages and drawbacks.
Kronborg O; Regula J
Dig Dis; 2007; 25(3):270-3. PubMed ID: 17827954
[TBL] [Abstract][Full Text] [Related]
36. Barriers of and facilitators to physician recommendation of colorectal cancer screening.
Guerra CE; Schwartz JS; Armstrong K; Brown JS; Halbert CH; Shea JA
J Gen Intern Med; 2007 Dec; 22(12):1681-8. PubMed ID: 17939007
[TBL] [Abstract][Full Text] [Related]
37. Challenges in the management of positive fecal occult blood tests.
Rao SK; Schilling TF; Sequist TD
J Gen Intern Med; 2009 Mar; 24(3):356-60. PubMed ID: 19130147
[TBL] [Abstract][Full Text] [Related]
38. Persistent demographic differences in colorectal cancer screening utilization despite Medicare reimbursement.
Ko CW; Kreuter W; Baldwin LM
BMC Gastroenterol; 2005 Mar; 5():10. PubMed ID: 15755323
[TBL] [Abstract][Full Text] [Related]
39. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008.
Choi KS; Lee HY; Jun JK; Shin A; Park EC
J Gastroenterol Hepatol; 2012 Jun; 27(6):1070-7. PubMed ID: 22004224
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic testing following fecal occult blood screening in the elderly.
Lurie JD; Welch HG
J Natl Cancer Inst; 1999 Oct; 91(19):1641-6. PubMed ID: 10511591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
